Last reviewed · How we verify

Type 2 Diabetes Mellitus with multiple risk factors for CHD — Treatment Landscape & Competitive Intelligence

Type 2 Diabetes Mellitus with multiple risk factors for CHD (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Type 2 Diabetes Mellitus with multiple risk factors for CHD, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Caduet Amlodipine Besylate Pfizer Inc. Dihydropyridine calcium channel blocker L-type calcium channel

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Type 2 Diabetes Mellitus with multiple risk factors for CHD

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Type 2 Diabetes Mellitus with multiple risk factors for CHD:

Cite this brief

Drug Landscape (2026). Type 2 Diabetes Mellitus with multiple risk factors for CHD — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/type-2-diabetes-mellitus-with-multiple-risk-factors-for-chd. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing